Abstract
Background
Hypofractionated proton therapy (HFPT) is expected to become an effective treatment approach for localized prostate cancer (PCa). The purpose of this study was to evaluate differences in acute toxicity among patients with localized PCa treated with either conventional fractionated proton therapy (CFPT) or HFPT.
Methods
A total of 526 eligible patients treated with proton therapy between February 2013 and May 2016 in three phase II trials were analyzed. We prescribed 74 gray relative biological effectiveness equivalents [Gy (RBE)]/37 fractions for low-risk patients and 78 Gy (RBE)/39 fractions for intermediate- and high-risk patients in the CFPT group (n = 254) and 60 Gy (RBE)/20 fractions for low-risk and 63 Gy (RBE)/21 fractions for intermediate- and high-risk patients in the HFPT group (n = 272). Patients were evaluated for acute toxicity with the Common Terminology Criteria for Adverse Events, version 4.0, and urinary quality-of-life change using the International Prostate Symptom Score (IPSS).
Results
No grade ≥3 acute toxicity was observed in either group. Among acute genitourinary toxicities, grade 2 rates were 15% (n = 38) in CFPT and 5.9% (n = 16) in HFPT (P ≤ 0.001). The median baseline IPSSs of the CFPT and HFPT groups were 7 (0–29) and 6 (0–31), respectively (P = 0.70). One-month post-treatment scores were 9 (0–32) and 11 (0–32), respectively (P = 0.036), and 6-month post-treatment scores were 7 (0–30) and 7 (0–33), respectively (P = 0.88). There were no significant differences in acute gastrointestinal toxicity between the two groups.
Conclusion
Our results demonstrated the safety of HFPT for localized PCa patients in terms of acute toxicity.
Similar content being viewed by others
References
NCCN clinical practice guidelines in oncology (NCCN guidelines) for prostate cancer. http://www.nccn.org. Accessed 30 June 2017
Hoppe B, Henderson R, Mendenhall WM et al (2011) Proton therapy for prostate cancer. Oncology (Williston Park) 25:644–650, 652
Pugh TJ, Munsell MF, Choi S et al (2013) Quality of life and toxicity from passively scattered and spot-scanning proton beam therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 87:946–953
Mendenhall NP, Hoppe BS, Nichols RC et al (2014) Five-year outcomes from 3 prospective trials of image-guided proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys 88:596–602
Brenner DJ, Martinez AA, Edmundson GK et al (2002) Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 52:6–13
Fowler J, Chappell R, Ritter M (2001) Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 50:1021–1031
Koontz BF, Bossi A, Cozzarini C et al (2015) A systematic review of hypofractionation for primary management of prostate cancer. Eur Urol 68:683–691
Zietman AL (2016) Making radiation therapy for prostate cancer more economical and more convenient. J Clin Oncol 34:2323–2324
Dearnaley D, Syndikus I, Mossop HK et al (2016) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 17:1047–1060
Incrocci L, Wortel RC, Alemayehu WG et al (2016) Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 17:1061–1069
Manabe Y, Shibamoto Y, Sugie C et al (2014) Toxicity and efficacy of three dose-fractionation regimens of intensity-modulated radiation therapy for localized prostate cancer. J Radiat Res 55:494–501
Mendenhall NP, Li Z, Hoppe BS et al (2012) Early outcomes from three prospective trials of image-guided proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys 82:213–221
Bryant C, Smith TL, Henderson RH et al (2016) Five-year biochemical results, toxicity, and patient-reported quality of life after delivery of dose-escalated image guided proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys 95:422–434
Fang P, Mick R, Deville C et al (2015) A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer. Cancer (Phila) 121:1118–1127
Kim YJ, Cho KH, Pyo HR et al (2013) A phase II study of hypofractionated proton therapy for prostate cancer. Acta Oncol 52:477–485
Vargas CE, Hartsell WF, Dunn M, et al (2015) Hypofractionated versus standard fractionated proton-beam therapy for low-risk prostate cancer: interim results of a randomized trial PCG GU 002. Am J Clin Oncol (Epub ahead of print, Oct. 29, 2015)
Toshito T, Omachi C, Kibe Y et al (2016) A proton therapy system in Nagoya Proton Therapy Center. Australas Phys Eng Sci Med 39:645–654
Hashimoto S, Shibamoto Y, Iwata H et al (2016) Whole-pelvic radiotherapy with spot-scanning proton beams for uterine cervical cancer: a planning study. J Radiat Res 57:524–532
Moyers MF, Miller DW, Bush DA et al (2001) Methodologies and tools for proton beam design for lung tumors. Int J Radiat Oncol Biol Phys 49:1429–1438
Park PC, Zhu XR, Lee AK et al (2012) A beam-specific planning target volume (PTV) design for proton therapy to account for setup and range uncertainties. Int J Radiat Oncol Biol Phys 82:329–336
Hynds S, McGarry CK, Mitchell DM et al (2011) Assessing the daily consistency of bladder filling using an ultrasonic Bladderscan device in men receiving radical conformal radiotherapy for prostate cancer. Br J Radiol 84:813–818
Barry MJ, Fowler FJ, O’Leary MP et al (1992) The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 148:1549–1557
Kanda Y (2013) Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant 48:452–458
Catton CN, Lukka H, Gu CS et al (2017) Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol 35:1884–1890
Hopewell JW, Nyman J, Turesson I (2003) Time factor for acute tissue reactions following fractionated irradiation: a balance between repopulation and enhanced radiosensitivity. Int J Radiat Oncol Biol 79:513–524
Benjamin LC, Tree AC, Dearnaley DP (2017) The role of hypofractionated radiotherapy in prostate cancer. Curr Oncol Rep 19:30
Pollack A, Walker G, Horwitz EM et al (2013) Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol 31:3860–3868
Tomita N, Oze I, Shimizu H et al (2015) International prostate symptom score (IPSS) change and changing factor in intensity-modulated radiotherapy combined with androgen deprivation therapy for prostate cancer. Nagoya J Med Sci 77:637–646
Norkus D, Karklelyte A, Engels B et al (2013) A randomized hypofractionation dose escalation trial for high risk prostate cancer patients: interim analysis of acute toxicity and quality of life in 124 patients. Radiat Oncol 8:206
Haustermans KM, Hofland I, Van Poppel H et al (1997) Cell kinetic measurements in prostate cancer. Int J Radiat Oncol Biol Phys 37:1067–1070
Paganetti H (2014) Relative biological effectiveness (RBE) values for proton beam therapy. Variations as a function of biological endpoint, dose, and linear energy transfer. Phys Med Biol 59:R419–R472
Girdhani S, Sachs R, Hlatky L (2013) Biological effects of proton radiation: what we know and don’t know. Radiat Res 79:257–272
Iwata H, Ogino H, Hashimoto S et al (2016) Spot scanning and passive scattering proton therapy: relative biological effectiveness and oxygen enhancement ratio in cultured cells. Int J Radiat Oncol Biol Phys 95:95–102
Acknowledgements
The authors thank Dr. Chihiro Omachi as a member of proton therapy physics, and Dr. Keisuke Yasui and Mr. Kensuke Hayashi as a member of proton therapy technology, for their valuable help in this research.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors have read the journal’s policy on conflicts of interest and have none to declare.
Funding
No specific funding was disclosed.
Ethics approval
The data of this study were extracted from ongoing prospective phase II clinical trials based on protocols approved by the Institutional Review Board (IRB) of Nagoya City Hospital. The IRB numbers are 14-02-17 (14) and 14-02-18 (15) and 14-02-19 (16).
Informed consent
Informed consent was obtained from each participant.
About this article
Cite this article
Nakajima, K., Iwata, H., Ogino, H. et al. Acute toxicity of image-guided hypofractionated proton therapy for localized prostate cancer. Int J Clin Oncol 23, 353–360 (2018). https://doi.org/10.1007/s10147-017-1209-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-017-1209-8